SCHEMBL339351

SCHEMBL339351

O=Cc1ccccc1Nc1c(CCC(=O)O)cccc1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 6/20 0.48
PTGER3 P43115 6/20 0.48
PTGER1 P34995 5/20 0.48
PTGER2 P43116 5/20 0.48
FFAR1 O14842 4/20 0.43
FFAR4 Q5NUL3 3/20 0.43
FOLH1 Q04609 1/20 0.39
PTGS2 P35354 3/20 0.39
TTR P02766 2/20 0.39
AKR1B10 O60218 1/20 0.39
UGT1A9 O60656 1/20 0.39
TRPA1 O75762 1/20 0.39
ABCB11 O95342 1/20 0.39
MT-CO2 P00403 1/20 0.39
ALB P02768 1/20 0.39
CXCL8 P10145 1/20 0.39
UGT1A6 P19224 1/20 0.39
UGT1A1 P22309 1/20 0.39
PTGS1 P23219 1/20 0.39
CXCR1 P25024 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2563233 0.73 KEAP1 (0.50) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL6053663 0.73 PTGER4 (0.81) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL28557306 0.73 PTGER1 (0.40) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL340105 0.73 CXCL8 (0.51) PTGS2CXCL8PTGS1SLC22A6LMNA
SCHEMBL1261128 0.72 PTGER4 (0.77) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL31212507 0.72 PTGER4 (0.77) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL2994014 0.70 PTGER4 (0.64) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL27782837 0.69 PTGER1 (0.49) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL4979854 0.68 PTGER4 (0.62) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL29174155 0.68 CD274 (0.64) PTGER4PTGER3PTGER1PTGER2FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181175-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2015-11-10 US disclosed
EP-2387558-B1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2014-08-27 EP disclosed
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2014-06-26 US disclosed
US-8703990-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2014-04-22 US disclosed
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID NOVARTIS AG (CH) 2012-01-19 US disclosed
EP-2387558-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) 2011-11-23 EP disclosed
US-20110253230-A1 Temperature Sensitive Valve Having Shape Memory Actuator OMNITEK PARTNERS LLC (US) 2011-10-20 US disclosed
WO-2010081410-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 PTGER4 1338/4885PTGER3 909/4885PTGER1 998/4885
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 PTGER4 1338/4885PTGER3 909/4885PTGER1 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.